Company Summary
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
